新製品

PI3K/Akt/mTOR
JAK/STAT
Cell Cycle
DNA Damage
TGF-beta/smad
GPCR & G Protein
Protein Tyrosine Kinase
Epigenetics
NF-κB
Metabolism
Proteases
Microbiology
Apoptosis
MAPK
Angiogenesis
Stem Cell & Wnt
Ubiquitin
Neuronal Signaling
Others

製品コード	製品名称	製品説明	添加時期
E1710	LY2780301	LY2780301 is a highly selective adenosine triphosphate (ATP)-competitive dual inhibitor of p70S6K and Akt. LY2780301 binds to Akt, inhibiting its activity, which consequently blocks the PI3K/Akt signaling pathway which leads to reduced cell proliferation and the initiation of apoptosis in tumor cells.	Apr 08 2024
S8267	RapaLink-1	RapaLink-1, a third-generation bivalent inhibitor of mTOR, combines Rapamycin with MLN0128 using an inert chemical linker. It demonstrates efficacy against resistant mutants of malignant brain tumors and inhibits cancer cell progression by binding to mesenchymal markers.	Apr 06 2024
E1604	Vevorisertib trihydrochloride	Vevorisertib trihydrochloride(ARQ 751 trihydrochloride) is a selective, allosteric inhibitor of pan-AKT and AKT1-E17K mutant with Kd values of 1.2 nM and 8.6 nM, respectively. It also has IC50 values of 0.55, 0.81, and 1.3 nM for AKT1, AKT2, and AKT3, respectively and can be used for the research of cancer.	Jan 16 2024
E1579	UCL-TRO-1938	UCL-TRO-1938 is a potent allosteric activator of PI3Kα with an EC50 value of approximately 60 μM. UCL-TRO-1938 can induce cell proliferation and has cardioprotective and neural regeneration effects.	Nov 22 2023
E2981	PI4KIIIbeta-IN-10	PI4KIIIbeta-IN-10 is a potent inhibitor of PI4KIIIβ with an IC50 of 3.6 nM. It also exhibits weak inhibition of PI3KC2γ, PI3Kα, and PI4KIIIα, and <20% inhibition at concentrations up to 20 µM for PI4K2α, PI4K2β, and PI3Kβ.	Oct 27 2023
E4345	L-Norvaline	L-Norvaline is a non-proteinogenic amino acid, an isomer of valine, and an inhibitor of arginase and p70 ribosomal S6 kinase 1 (p70S6K1) kinase. L-norvaline enhances NO production from activated macrophages.	Oct 11 2023
E1388	ISA-2011B	ISA-2011B is an inhibitor of phosphatidylinositol-4-phosphate 5-kinase-α (PIP5Kα). ISA-2011B exhibits anti-proliferative activity and induces apoptosis in prostate cancer cells.	Aug 28 2023
E2947	Recilisib	Recilisib (ON01210, EX-RAD) is a radioprotectant that activates the activity of AKT and PI3K in cells. It has been studied as prophylactic (use prior to radiation exposure) and therapeutic (after exposure to radiation) drug.	Jul 09 2023
E2933	MOMIPP	MOMIPP, a macropinocytosis inducer, is a PIKfyve inhibitor. MOMIPP readily penetrates the blood-brain barrier and is moderately effective in suppressing progression of intracerebral glioblastoma xenografts.	Jun 12 2023
E2371	YLF-466D	YLF-466D is an AMPK activator that inhibits platelet aggregation with IC50 of 84 μM.	Jan 06 2023

製品コード	製品名称	製品説明	添加時期
E1526	Zasocitinib	Zasocitinib( NDI-034858, TAK-279) is a TYK2 inhibitor, which is currently being investigated in a phase IIb trial for moderate-to-severe plaque psoriasis.	Oct 11 2023
S8802	Delgocitinib (JTE-052)	Delgocitinib (JTE-052) is a specific JAK inhibitor with IC50s of 2.8, 2.6, 13 and 58 nM for JAK1, JAK2, JAK3 and Tyk2, respectively.	Mar 29 2023
S0456	inS3-54-A18	inS3-54A18 is a potent inhibitor of STAT3 with anti-cancer properties.	Oct 28 2022
S1349	SC99	SC99 is an orally active, selective STAT3 inhibitor targeting JAK2-STAT3 pathway by docking into the ATP-binding pocket of JAK2, also inhibits phosphorylation of JAK2and STAT3 with no effects on the other kinases associated with STAT3 signaling.	Jul 28 2022
E0793	G5-7	G5-7 is an orally active and allosteric JAK2 inhibitor, selectively inhibits JAK2 mediated phosphorylation and activation of EGFR (Tyr1068) and STAT3 by binding to JAK2.	Jul 21 2022
E2644	Tetramethylcurcumin	Tetramethylcurcumin (FLLL31), a small-molecule signal transducer and activator of transcription 3 (STAT3) inhibitor derived from curcumin, binds selectively to Janus kinase 2 and the STAT3 Src homology-2 domain, which serve crucial roles in STAT3 dimerization and signal transduction.	Jul 15 2022
S0986	SC-1	SC-1 (1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea, STAT3-IN-7), a Sorafenib analogue and potently inhibits the phosphorylation of STAT3, induces cell apoptosis through SHP-1 dependent STAT3 inactivation.	Jun 30 2022
E2398	STAT5-IN-2	STAT5-IN-2 inhibits the growth of acute and chronic myeloid leukemia cells and the phosphorylation and transcriptional activity of STAT5, but not STAT3, AKT, or Erk1/2 phosphorylation, with minimal effects on bone marrow stromal cells that play vital functions in the microenvironment of hematopoietic and leukemic cells.	Jun 24 2022
E0485	Stafia-1	Stafia-1 is the first STAT5a inhibitor that inhibits STAT5a (IC50=22.2 μM, Ki=10.9 μM) with at least 9‐fold selectivity over STAT5b and higher selectivity against other STAT family members.	Feb 21 2022
A2018	Panitumumab (anti-EGFR)	Panitumumab (anti-EGFR, ABX-EGF) is a recombinant, fully human IgG2 monoclonal antibody that binds to the epidermal growth factor receptor (EGFR).	Dec 16 2021

製品コード	製品名称	製品説明	添加時期
E1597	RMC-6236	RMC-6236 (RAS-IN-2) is a RAS(ON) multi-selective noncovalent inhibitor of the active, GTP-bound state of both mutant and wild-type variants of canonical RAS isoforms with broad therapeutic potential. RMC-6236 exhibits strong anticancer efficacy in RAS-addicted cell lines, especially those with mutations at codon 12 of KRAS.	Apr 10 2024
E1653	CCT241533 hydrochloride	CCT241533 hydrochloride is an ATP competitive, potent, and selective inhibitor of CHK2 with an IC50 of 3 nM and a Ki of 1.16 nM and shows minimal cross-reactivity against a panel of kinases. CCT241533 inhibits CHK2 activity in human tumor cell lines when subjected to DNA damage.	Apr 06 2024
E1670	MKI-1	MKI-1(MASTL Kinase Inhibitor-1) is an small-molecule inhibitor of MASTL (microtubule-associated serine/threonine kinase-like) with an IC50 9.9 μM in kinase assay. It also exerts antitumor and radiosensitizer activities through PP2A-mediated c-Myc inhibition in breast cancer models.	Feb 26 2024
E4578	Trilaciclib dihydrochloride	Trilaciclib dihydrochloride(G1T28 dihydrochloride) is a potent inhibitor of CDK4/cyclin D1 and CDK6/cyclin D3 with IC50s of 1 nM and 4 nM for CDK4 and CDK6, respectively. Trilaciclib hydrochloride regulates cell proliferation and protects against chemotherapy toxicity in murine and canine bone marrow cells.	Feb 06 2024
E1667	LY2880070	LY2880070 is an orally active inhibitor of CHK1. LY2880070 can be used as an anticancer agent and shows promise in preclinical models of pancreatic ductal adenocarcinoma (PDAC) when used in combination with DNA-damaging agents.	Jan 10 2024
E1564	BI-2493	BI-2493, a structural analogue of BI-2865, is a highly selective inhibitor of pan-KRAS. BI-2493 attenuates tumor growth and can be used for cancer research.	Jan 07 2024
E1435	Tinengotinib	Tinengotinib (TT-00420) is a novel multiple kinase inhibitor that strongly inhibits Aurora A/B with IC50 values of 1.2/3.3 nM respectively. It also exhibits potent inhibitory activity on FGFR1/2/3, VEGFR1, JAK1/2, and CSF1R and can be used to treat several prominent signaling pathways in triple-negative breast cancer(TNBC).	Jan 01 2024
E1605	Avotaciclib trihydrochloride	Avotaciclib trihydrochloride(BEY1107 trihydrochloride) is a potent and orally active inhibitor of cyclin dependent kinase 1 (CDK1). It can be used for the research of locally advanced or metastatic pancreatic cancer.	Dec 17 2023
S8395	INDY	INDY, a benzothiazole derivative is a potent and ATP-competitive inhibitor of Dyrk1A and Dyrk1B with an IC50 value of 0.24 μM and Ki value of 0.18 μM, respectively. INDY diminishes the self-renewal capacity of normal and tumorigenic cells in primary Glioblastoma (GBM) cell lines and neural progenitor cells.	Dec 11 2023
E1495	PF-07220060 (CDK4/6-IN-6)	PF-07220060 (CDK4/6-IN-6) is a potent CDK4/CDK6 inhibitor with a Ki of 0.6 nM and 13.9 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively.	Oct 27 2023

製品コード	製品名称	製品説明	添加時期
S9716	H3B-8800	H3B-8800 is a potent and orally active modulator of SF3B splicing. H3B-8800 interacts directly with the SF3b complex, demonstrating anti-cancer properties. H3B-8800 holds promise for studying acute myeloid leukemia (AML) with SF3B1 mutations.	Apr 10 2024
E1905	Nalidixic acid sodium salt	Nalidixic acid sodium salt is an inhibitor of bacterial DNA gyrase and topoisomerase IV, essential enzymes for DNA supercoiling during replication, making it an effective quinolone antibiotic against both gram-positive and gram-negative bacteria.	Apr 06 2024
E1614	OUL232	OUL232 (Compound 27) is an potent inhibitor of mono-ADP-ribosylation (mono-ARTs) PARP10 with IC50 of 7.8 nM. It also inhibits PARP7, PARP11, PARP12, PARP14, and PARP15 at nM potencies.	Feb 26 2024
E1769	Merbarone	Merbarone(NSC 336628) is a catalytic inhibitor of topoisomerase II with IC50 of 120 μM, with anti-proliferative activity against human cancer cells. Merbarone acts primarily by blocking topoisomerase II-mediated DNA cleavage.	Jan 17 2024
E1739	MST-312	MST-312(Telomerase Inhibitor IX) is an inhibitor of telomerase. MST-312 is a chemically modified derivative of green tea epigallocatechin gallate (EGCG). MST-312 exhibits high chemical stability, lowers the effective dose in the induction of telomere shortening, and lowers drug resistance. MST-312 can be used for the research of cancer. MST-312 can also be used as a promising strategy in the treatment of multiple myeloma (MM).	Jan 10 2024
E1512	M3541	M3541 is a potent and selective inhibitor of ATM kinase activity with an IC50 value of 0.25 nM in cell-free assays. M3541 suppresses double-strand breaks (DSB) repair, clonogenic cancer cell growth and potentiates antitumor activity of ionizing radiation in cancer cell lines.	Dec 06 2023
E1529	ART812	ART812 is an orally active DNA polymerase Polθ inhibitor with an IC50 value of 7.6 nM.	Nov 06 2023
E1469	ITF3756	ITF3756 is a selective histone deacetylase 6 (HDAC6) inhibitor bearing a pentaheterocyclic scaffold. It can be used in research of autoimmune disorders, neurodegenerative diseases, and cancer.	Oct 17 2023
E1596	AOH1996	AOH1996 is an orally active small-molecule PCNA inhibitor with potential anti-tumor activity. It enhances the interaction between PCNA and RPB1, the largest subunit of RNA polymerase II.	Sep 21 2023
E1425	Nesuparib	Nesuparib (JPI-547, NOV140201) is a potential inhibitor of both PARP and tankyrases, with IC50 of 0.005 μM, 0.001 μM, 0.002 μM, and ND for TNKS1, TNKS2, PARP1, and PARP2, respectively. Nesuparib exhibits anti-tumor activity in BRCA-deficient xenograft models.	Sep 06 2023

製品コード	製品名称	製品説明	添加時期
A3071	Anti-TGFb1 (NIS793)	Anti-TGFb1 (NIS793) is a monoclonal antibody targeting TGF-β. It can be used in metastatic melanoma and non-small cell-lung cancer. MW :143.78 KD	Oct 11 2023
A2694	Anti-TGFb1 (SRK181)	Anti-TGFb1 (SRK181) is a monoclonal antibody directed against latent human transforming growth factor (TGF)-beta 1 with potential antineoplastic activity. MW : 150 kD.	Oct 11 2023
A2695	Anti-TGFb1 (M7824)	Anti-TGFb1 (M7824) is a bifunctional monoclonal antibody targeting programmed death ligand 1 (PD-L1) and transforming growth factor beta 1 (TGFb1). It exhibits anti-tumor efficacy against breast and colon carcinomas.	Oct 11 2023
A2422	Garetosmab (Anti-INHBA / Activin A)	Garetosmab (Anti-INHBA / Activin A) is a fully human IgG4 monoclonal antibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans progressiva (FOP) research. MW: 145.5 kD.	Aug 10 2023
A2336	Fresolimumab (Anti-TGFb1)	Fresolimumab (Anti-TGFb1) is a pan-specific, recombinant, fully human monoclonal antibody directed against human transforming growth factor (TGF) beta 1, 2, and 3 with potential antineoplastic activity. MW : 145.5 KD.	Aug 10 2023
A2595	Bimagrumab (Anti-ACVR2B)	Bimagrumab (Anti-ACVR2B) is a human monoclonal antibody targeting activin type II receptor (ActRII). It can be used for the treatment of pathological muscle loss and weakness. MW : 150 KD.	Aug 10 2023
E2394	TGFβRI-IN-3	TGFβRI-IN-3 represents a highly selective TGFβR1 inhibitor that has potential applications in immuno-oncology, inhibits TGFβR1 at an IC50 of 0.79 nM with 2000-fold selectivity against MAP4K4.	Jul 08 2022
E2368	N-Desmethyltamoxifen hydrochloride	N-Desmethyltamoxifen hydrochloride (N-Desmethyl tamoxifen HCl), the primary metabolite of tamoxifen, is an estrogen response modifer and protein kinase C inhibitor with IC50 of 25 µM.	Jul 08 2022
E2839	Bisindolylmaleimide VIII (acetate)	Bisindolylmaleimide VIII (acetate) (Ro 31-7549 acetate) is a potent and selective protein kinase C (PKC) inhibitor with an IC50 of 158 nM for rat brain PKC, also exerting IC50s of 53, 195, 163, 213, and 175 nM for PKC-α, PKC-βI, PKC-βII, PKC-γ, PKC-ε, respectively.	Jun 30 2022
E0786	N-Desmethyltamoxifen	N-Desmethyltamoxifen, the major metabolite of Tamoxifen in humans and a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen, also is a potent regulator of ceramide metabolism in human AML cells, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation.	Jun 29 2022

製品コード	製品名称	製品説明	添加時期
E4585	N-Arachidonyldopamine	N-Arachidonyldopamine is a potent agonist of cannabinoid receptor 1 (CB1), with a Ki of 250 nM in rat brain membranes, showing 40-fold selectivity for CB1 over CB2 receptors. It also triggers intracellular calcium mobilization in N18TG2 neuroblastoma cells.	Apr 17 2024
E1036	BMS-986278	BMS-986278 is a potent and orally active antagonist of lysophosphatidic acid receptor 1 (LPA1). BMS-986278 exhibits Kbs of 6.9 nM and 4.0 nM for human and mouse LPA1, respectively, and is widely used in the research of pulmonary fibrotic diseases.	Apr 14 2024
E1356	BI-0474	BI-0474 is a potent inhibitor of KRASG12C with an IC50 value of 7.0 nM. It inhibits GDP-KRAS::SOS1 protein-protein interactions. It exhibits anti-proliferative and anti-tumour activity and can be used in cancer research.	Mar 24 2024
S9852	Orforglipron	Orforglipron(LY3502970) is a non-peptidal agonist of glucagon-like peptide 1(GLP-1) receptor. It can be used efficiently in glycemic control and weight reduction in type 2 diabetes mellitus (T2DM), obesity or both.	Jan 24 2024
E1746	Protokylol hydrochloride	Protokylol hydrochloride(Caytine hydrochloride, JB-251 hydrochloride) is a salt form of protokylol and is an agonist of β-adrenergic receptor. Protokylol hydrochloride is also used as a bronchodilator.	Jan 07 2024
E4031	8-Cyclopentyl-1,3-dimethylxanthine	8-Cyclopentyl-1,3-dimethylxanthine is a selective adenosine A1 receptor antagonist with Ki's of 10.9 nM and 1440 nM for A1 receptor and A2 receptor, respectively.	Nov 26 2023
E2986	ONO-AE3-208	ONO-AE3-208(AE 3-208) is a selective and orally active EP4 receptor antagonist with a Ki of 1.3 nM, less potent to EP3, FP, and TP receptors with Ki of 30 nM, 790 nM, and 2400 nM, respectively.	Nov 19 2023
E1280	Ubrogepant	Ubrogepant (MK-1602) is an antagonist of human calcitonin gene-related peptide receptor (CGRP). It potently blocks human α–CGRP–stimulated cAMP responses with an IC50 of 0.081 nM in human CGRP receptor-expressing HEK293 cells.	Oct 27 2023
E1318	Mavorixafor	Mavorixafor (AMD-070) is a potent, selective CXCR4 antagonist, with an IC50 value of 13 nM against CXCR4 125I-SDF binding.	Oct 13 2023
A3116	Anti-GLP1R	Anti-GLP1R is a humanized antibody targeting GLP-1 receptor (GLP-1R). It can be used in therapy for type 2 diabetes mellitus. MW : 144.5 KD.	Oct 11 2023

製品コード	製品名称	製品説明	添加時期
E1749	limertinib	limertinib (ASK120067) is an irreversible third-generation inhibitor of EGFR^T790M with IC50 of 0.3 nM, with selectivity over EGFR^WT having IC50 of 6.0 nM. It exhibits potent anti-proliferation activity in non-small cell lung cancer (NSCLC) tumor cells.	Jan 23 2024
E4449	AG 825	AG-825 (Tyrphostin AG-825) is a potent and selective inhibitor of ErbB2 with IC50 values of 0.15 µM. It also inhibits PDGFR autophosphorylation with IC50 value of 40 µM. It exhibits anti-cancer activity and significantly induces apoptosis in cancer cells.	Jan 22 2024
E1634	CH6953755	CH6953755 is a potent, orally active, and selective inhibitor of YES1 kinase with an IC50 of 1.8 nM. CH6953755 demonstrates antitumor activity against YES1 gene-amplified cancers.	Jan 21 2024
E4580	Sovleplenib	Sovleplenib(HMPL-523) is a highly potent and selective SYK inhibitor with IC50 of 0.025 μM, that exhibits anti-tumor activities in vitro and in vivo. Sovleplenib exhibits synergistic activities in combination with BTK, PI3Kδ, and Bcl2 family inhibitors in killing human-diffused large B cell lymphoma (DLBCL).	Jan 17 2024
E1744	UNC5293	UNC5293 is a potent, highly selective, orally available inhibitor of MER receptor tyrosine kinase (MERTK) with IC50 of 0.9 nM and Ki 0.19 nM.	Jan 09 2024
E1727	Pimicotinib	Pimicotinib (ABSK021) is an orally bioavailable inhibitor of colony stimulating factor 1 receptor (CSF1R). It enhances antitumor T-cell immune responses and inhibits the proliferation of tumor cells having potential immunomodulatory and antineoplastic activities.	Jan 07 2024
E1409	Zidesamtinib	Zidesamtinib (NVL-520) is a potent brain-penetrating inhibitor of ROS1 tyrosine kinase with IC50 of 0.7 nM for wild-type ROS1 . It acts as a potential antineoplastic agent and can be used for the research of cancer.	Dec 11 2023
E1732	Itacnosertib (TP-0184)	Itacnosertib (TP-0184) is a small-molecule inhibitor of the BMP type 1 receptor ALK2 (also known as ACVR1). Itacnosertib reduces hepcidin induction and elevated serum iron levels in turpentine and lung cancer mouse models of ACD.	Nov 19 2023
E1507	Zilurgisertib fumarate	Zilurgisertib fumarate(INCB-000928 fumarate, NBU-928 fumarate) is a selective ALK 2 inhibitor.It is under development for the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.	Nov 08 2023
E1509	Bezuclastinib	Bezuclastinib(CGT9486; PLX 9486) is a potent inhibitor of c-kit and c-kit D816V with an IC50 value of <1 μM. Bezuclastinib is also an inhibitor of tyrosine kinase.	Nov 05 2023

製品コード	製品名称	製品説明	添加時期
E1728	STC-15	STC-15 is an oral, small-molecule inhibitor of RNA methyltransferase METTL3. It inhibits tumor growth through the activation of anti-cancer immune responses associated with increased interferon signaling and synergizes with T-cell checkpoint blockade.	Apr 16 2024
E1554	Tefinostat(CHR-2845)	Tefinostat(CHR-2845) is a monocyte/macrophage-targeted inhibitor of pan-histone deacetylase (HDAC). Tefinostat undergoes cleavage mediated by the intracellular esterase human carboxylesterase-1 (hCE-1) to yield the active acid CHR-2847. In vitro studies reveal a specific heightened sensitivity of monocytoid leukemias to tefinostat.	Mar 27 2024
S9734	Bomedemstat	Bomedemstat(IMG-7289) is an orally active and irreversible inhibitor of LSD1(lysine-specific demethylase 1). Bomedemstat exhibits the ability to enhance methylation levels of H3K4 and H3K9, subsequently leading to modifications in gene expression. Bomedemstat demonstrates anti-cancer properties by restraining cancer cell proliferation and prompting apoptosis.	Mar 12 2024
E1163	MS177	MS177 is an EZH2-targeting PRTOAC degrader and a potent inhibitor of enzymatic EZH2, that effectively depletes both canonical EZH2–PRC2 and noncanonical EZH2–cMyc complexes. MS177 induces leukemia cell growth inhibition, apoptosis, and cell cycle progression arrest.	Feb 21 2024
E1711	FHT-1015	FHT-1015 is a potent, small-molecule, allosteric inhibitor of SMARCA4/SMARCA2 ATPase with IC50 values ≤10 nM. FHT-1205 decreases PD1+TIM3+ cells and cytokine expression in vivo.	Jan 21 2024
E1658	PRT543	PRT543 is a potent and selective inhibitor of protein arginine methyltransferase 5 (PRMT5) with broad antitumor activity in vitro and in vivo. It also inhibits the methyltransferase activity of the PRMT5/MEP50 complex with an IC50 of 10.8 nM.	Jan 09 2024
E1618	TC-S 7009	TC-S 7009 is a potent and selective inhibitor of HIF-2α with a Kd value of 81 nM. TC-S 7009 is more selective for HIF-2α than HIF-1α. It disrupts HIF-2α heterodimerization, decreases DNA-binding activity, and reduces HIF-2α target gene expression.	Dec 20 2023
E1497	Tulmimetostat	Tulmimetostat (CPI-0209) is an orally bioavailable and selective inhibitor of EZH2 that has therapeutic potential for androgen receptor-dependent prostate cancer.	Nov 26 2023
E1733	PBIT	PBIT is a specific inhibitor of the Jumonji AT-rich Interactive Domain 1 (JARID1) enzymes. It inhibits JARID1B (KDM5B/PLU1), JARID1Aand JARID1C with an IC50 of 3 μM, 6 μM and 4.9 μM respectively. It is capable of inhibiting the multiplication of breast cancer cell lines expressing high levels of JARIDB1.	Nov 26 2023
S8545	TEN-010 (RG6146,Ro-6870810,(S)-JQ-35)	TEN-010 (RG6146, Ro-6870810,(S)-JQ-35) is an inhibitor of the Bromodomain and Extra-Terminal(BET) family bromodomain-containing proteins with potential antineoplastic activity.	Nov 21 2023

製品コード	製品名称	製品説明	添加時期
E1714	B022	B022 is a potent and selective NF-κB-inducing kinase (NIK) inhibitor with a Ki of 4.2 nM. B022 protects liver from toxin-induced inflammation, oxidative stress, and injury.	Dec 26 2023
E1575	EN450	EN450 is a cysteine-reactive covalent molecular glue degrader targeting NF-κB. It interacts with allosteric C111 in the E2 ubiquitin ligase UBE2D that induces the ternary complex formation between UBE2D and NFKB1. It exhibits anti-proliferative effects through a Cullin E3 ligase and proteasome-dependent mechanism.	Oct 17 2023
E1351	NF-κΒ activator 1	NF-κΒ activator 1(Compound 32) is a potent NF-κΒ activator, with an EC50 of 0.9 μM.	Apr 20 2023
E2661	Chitosan oligosaccharide	Chitosan oligosaccharide (COS) is an oligomer of β-(1➔4)-linked d-glucosamine, of which actions involve the modulation of several important pathways including the suppression of nuclear factor kappa B (NF-κB) and mitogen-activated protein kinases (MAPK) and the activation of AMP-activated protein kinase (AMPK).	Aug 10 2022
E0944	IMD-0560	IMD-0560 is an Inhibitor of nuclear factor kappa-B kinase (IKK) which can suppress the production of inflammatory cytokines and chemokines.	Jul 27 2022
E0812	CXD101	CXD101 (HDAC-IN-4) is a potent, selective and orally active class I histone deacetylase (HDAC) inhibitor with IC50s of 63 nM, 570 nM and 550 nM for HDAC1, HDAC2 and HDAC3, respectively.	Jul 21 2022
E0796	NF-κB-IN-1	NF-κB-IN-1 is a potent NF-κB signaling pathway inhibitor, which acts by directly inhibiting inhibitory κB kinase (IKK).	Jul 21 2022
S0844	NDMC101	NDMC101 inhibits osteoclastogenesis which also ameliorates paw swelling and inflammatory bone destruction, associating with the inhibition of such transcription factors as NF-κB and NFATc1 as well as multiple protein kinases, including p38, ERK, and JNK.	Jul 06 2022
E0783	SM-7368	SM-7368 is a potent NF-κB inhibitor that targets downstream of MAPK p38 activation, also inhibits TNF-α-induced MMP-9 upregulation.	Jun 29 2022
E0487	SP-8356	SP-8356, an anti-inflammatory synthetic verbenone derivative, is a CD147 inhibitor with respect to its regulation of breast cancer cell behavior and cancer progression.	Feb 21 2022

製品コード	製品名称	製品説明	添加時期
E1904	SKF-34288 hydrochloride	SKF-34288 hydrochloride(3-Mercaptopicolinic acid hydrochloride; 3-MPA hydrochloride) is an orally active, specific inhibitor of phosphoenolpyruvate carboxykinase (PEPCK) with Ki values of 2-9 μM. SKF-34288 hydrochloride is a potent hypoglycemic agent by inhibiting glucose synthesis. SKF-34288 hydrochloride also inhibits cell proliferation, induces myogenic differentiation in vitro.	Apr 14 2024
E1165	JAB-3068	JAB-3068 (SHP2-IN-6) is a potent allosteric inhibitor of SHP2. JAB-3068 enhances the anti-tumor activity of CD8+ T cells and can be used in combination to address non-responsive tumors alongside PD-1/PD-L1 antibodies.	Mar 20 2024
E1768	MEDICA16	MEDICA16 is an inhibitor of ATP-citrate lyase and also acts as an agonist of G protein-coupled receptor 40 (GPR40). It functions to blunt the development of insulin resistance in the JCR:LA-cp rat as well as it is a potent triacylglycerol-lowering agent.	Mar 14 2024
E1341	Cerivastatin sodium	Cerivastatin sodium, a sodium salt of cerivastatin, is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase with Ki of 1.3 nM. It is also a synthetic, enantiomerically pure, pyridine derivative that effectively reduces serum cholesterol levels at microgram doses.	Mar 12 2024
E1287	SB 204990	SB-204990, a γ-lactone prodrug of SB-201076, is a potent and specific inhibitor of ATP citrate lyase (ACLY). SB 204990 potently limits SARS-CoV-2 replication in vivo.	Feb 04 2024
E1627	BMS493	BMS493 is an inverse agonist of pan retinoic acid receptor (RAR). It increases nuclear corepressor interaction with RARs and can be used as an inhibitor for the dietary and pharmacologic manipulation of retinoic acid (RA) activity in vivo and in vitro.	Feb 01 2024
E1685	D609	D609 is a selective, competitive inhibitor of phosphatidylcholine-specific phospholipase C (PC-PLC) with a Ki of 6.4 μM. It is an antioxidative protector and has antiviral and anti-inflammatory activity and also inhibits angiogenesis by preventing the synthesis of basement membrane (BM).	Feb 01 2024
E1520	NSC 663284	NSC 663284(DA-3003-10) is a potent, cell-permeable, and irreversible dual specificity phosphatase inhibitor of Cdc25, and exhibits an IC50 of 0.21 μM for Cdc25B2 and is 20 and 450-fold highly selective against Cdc25B2. NSC 663284 also inhibits NSD2 with an IC50 of 170 nM via a direct interaction with the catalytic SET domain.	Jan 30 2024
E1752	JNJ-42226314	JNJ-42226314 is a potent, selective, and reversible noncovalent inhibitor of monoacylglycerol lipase (MAGL). It enhances the expression of endocannabinoid 2-arachidonoylglycerol (2-AG) and exhibits antinociceptive efficacy in models of neuropathic and inflammatory pain.	Jan 22 2024
S6392	SHIN1(RZ-2994)	SHIN1 (RZ-2994) is an inhibitor of SHMT1/2 (human serine hydroxymethyltransferase 1 and 2) with IC50 values of 5 and 13 nM, respectively, in in vitro assay. SHIN1 hinders cell growth by gradually reducing purine levels.	Jan 21 2024

製品コード	製品名称	製品説明	添加時期
E4453	Cathepsin G Inhibitor I	Cathepsin G Inhibitor I exhibits reversible, competitive cathepsin G inhibition with IC50 and Ki values of 53 nM and 63 nM respectively. It can be used in antigen-processing studies and for modulation of T cell response in situ and in vivo.	Jan 22 2024
E1203	Sirpiglenastat	Sirpiglenastat (DRP-104) is a broad acting glutamine antagonist. It has anticancer effects by directly targeting tumor metabolism and simultaneously inducing a potent antitumor immune response with immunomodulatory and antineoplastic activities.	Dec 13 2023
E4466	Saquinavir Mesylate	Saquinavir mesylate (Ro 31-8959/003) is a potent inhibitor of HIV Protease used in antiretroviral therapy. It blocks proteolysis of polyproteins containing either wild-type or single-chain dimer retroviral proteinase (PR).	Nov 22 2023
E4454	DL-Thiorphan	Thiorphan (DL-3-Mercapto-2-benzylpropanoylglycine) is a selective NEP (neprilysin) inhibitor with an IC50 of 6.9 nM. It is also a potent inhibitor of enkephalinase, with antinociceptive activity.	Nov 19 2023
A3072	Zampilimab (Anti-TGM2 / Transglutaminase 2)	Zampilimab (Anti-TGM2 / Transglutaminase 2) is a monoclonal antibody targeting transglutaminase 2 (TG2). It has potential application in renal transplant. MW :143.48 KD.	Oct 11 2023
A2629	Anti-CTSS / Cathepsin S (Fsn0503h)	Anti-CTSS / Cathepsin S (Fsn0503h) is an antagonistic monoclonal antibody targeting cathepsin S. It has a potential to inhibit invasion of tumors, and targeting neovascularization in colorectal carcinoma. MW :144.28 KD.	Oct 11 2023
A2779	Befovacimab (Anti-TFPI)	Befovacimab (anti-TFPI) is a fully human monoclonal IgG2 antibody able to bind to tissue factor pathway inhibitors (TFPI) with the potential to be used in haemophilia A/B research. MW: 143.24 kD.	Oct 11 2023
A2786	Anti-BACE1 (Genentech anti-BACE1)	Anti-BACE1 (Genentech anti-BACE1) is a monoclonal anti-BACE1 antibody (mAb) that reduces endogenous BACE1 activity and amyloid-β (Aβ) production. It has the potential to treat Alzheimer's disease. MW: 144.22 KD.	Oct 11 2023
E4030	N-p-Tosyl-L-phenylalanine chloromethyl ketone	N-p-Tosyl-L-phenylalanine chloromethyl ketone (Tosyl phenylalanyl chloromethyl ketone, TPCK) is an irreversible inhibitor of chymotrypsin-like proteases that affect cell proliferation, apoptosis, and tumorigenesis.	Sep 11 2023
A2399	Andecaliximab (Anti-MMP9)	Andecaliximab (Anti-MMP9) is a recombinant chimeric IgG4 monoclonal antibody (mAb) that targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. MW: 145.5 kD.	Aug 10 2023

製品コード	製品名称	製品説明	添加時期
E1709	Fialuridine	Fialuridine(FIAU, DRG-0098, NSC 678514) is a nucleoside analog with antiviral activity. It blocks DNAsynthesis in human cytomegalovirus and hepatitis B, as well as herpes simplex.	Nov 10 2023
S8418	Zeocin (Phleomycin D1, zeomycin)	Zeocin (Phleomycin D1, Zeomycin, PLM D1), a glycopeptide antibiotic, is a member of the Bleomycin/Phleomycin family. It causes cell death by binding and cleaving DNA. It shows antiproliferative activities and strong cytotoxicity against HT-29 cells.	Oct 27 2023
E4472	Clavulanic acid	Clavulanic acid is a naturally occurring, powerful bacterial β-lactamase inhibitor. The beta-lactam ring found in clavulanic acid binds to the active site of beta-lactamase, resulting in enzyme inactivation and enhancing the antibacterial activity of beta-lactam antibiotics like amoxicillin.	Oct 19 2023
A2853	Gimsilumab (Anti-CSF2 / GM-CSF)	Gimsilumab (Anti-CSF2 / GM-CSF) is a human immunoglobulin G1 (IgG1) monoclonal antibody directed against the myeloid cell growth factor and inflammatory mediator granulocyte-macrophage colony-stimulating factor (GM-CSF) with potential immunomodulating activity. MW : 145.8 KD.	Oct 11 2023
A2854	Lenzilumab (Anti-CSF2 / GM-CSF)	Lenzilumab (Anti-CSF2 / GM-CSF) is a recombinant monoclonal antibody against the cytokine granulocyte macrophage colony-stimulating factor (GM-CSF), with potential immunomodulating activity. MW: 145.72 KD.	Oct 11 2023
A3124	Anti-HBsAg (OST 577)	Anti-HBsAg (OST 577) is monoclonal antibody targeting HBV surface antigen (HBsAg). It has the potential for chronic hepatitis B research. MW :144.6 KD.	Oct 11 2023
A3127	Motavizumab (Anti-RSV-F)	Motavizumab (Anti-RSV-F) is a monoclonal antibody targeting human RSV (respiratory syncytial virus). It can be used in respiratory syncytial virus infection in high-risk infants research. MW :145.32 KD.	Oct 11 2023
E4353	Ampicillin	Ampicillin (D-(-)-alpha-Aminobenzylpenicillin) is a broad-spectrum beta-lactam antibiotic against a variety of gram-positive and gram-negative bacteria. It exhibits a good minimum inhibitory concentration for Staphylococcus aureus, Escherichia coli, Hemophilus influenzae, and Streptococcus pneumoniae with MICs of 0.6–1 mg/L, 4 mg/L, 0.25 mg/L, and 0.03-0.06 mg/L, respectively.	Oct 11 2023
E1436	A2ti-2	A2ti-2 is a selective and low-affinity inhibitor of annexin A2/S100A10 heterotetramer (A2t)with an IC50 of 230 μM. It specifically disrupts the protein-protein interaction (PPI) between A2 and S100A10 and also prevents human papillomavirus type 16 (HPV16) infection.	Aug 17 2023
E4002	Potassium D-gluconate	Potassium D-gluconate(Potassium Gluconate) is an orally active carboxylic acid by the oxidation with antiseptic and chelating properties.	Aug 16 2023

製品コード	製品名称	製品説明	添加時期
E1713	FL118	FL118(10,11-(Methylenedioxy)-20(S)-camptothecin), a Camptothecin analog, is a potent and orally active inhibitor of Survivin. FL118 also selectively and independently inhibits three additional cancer-associated survival genes Mcl-1, XIAP, and cIAP2 in a p53 status-independent manner. FL118 displays potent antitumor activity and can be used in cancer research.	Feb 04 2024
E1874	Erastin2	Erastin2 is an inducer of ferroptosis. It also selectively inhibits xc(-) cystine/glutamate transporter. It induces ferroptosis in HT-1080, T98G, and A549 cells with the potential to treat neurodegenerative diseases.	Feb 01 2024
E1812	N6F11	N6F11 is an inducer of ferroptosis. N6F11 is bound to the RING domain of the E3 ubiquitin ligase tripartite motif containing 25 (TRIM25) in cancer cells to trigger TRIM25-mediated K48-linked ubiquitination of glutathione peroxidase 4 (GPX4), resulting in proteasomal degradation.	Jan 10 2024
E1734	OD36	OD36 is an inhibitor of RIPK2 with an IC50 value of 5.3 nM. OD36 is a macrocyclic inhibitor with potent binding to the ALK2 kinase ATP pocket.	Dec 24 2023
E1574	FSEN1	FSEN1 is a potent and non-competitive FSP1 inhibitor with an IC50 value of 313 nM. It triggers iron death in cancer cells by inhibiting FSP1 and can be used in research of cancer.	Nov 26 2023
E1537	MMRi62	MMRi62 is a ferroptosis inducer, targeting MDM2-MDM4 with Kd value of 1.39 μM. It exhibits a P53-independent pro-apoptotic activity against pancreatic ductal adenocarcinoma (PDAC) cells and induce autophagy.	Oct 31 2023
A2604	Tigatuzumab (Anti-TNFRSF10B / TRAILR2 / CD262)	Tigatuzumab (Anti-TNFRSF10B / TRAILR2 / CD262) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). It induces cell apoptosis of cancer cells and inhibits tumor growth and can be used for the research of cancer. MW :150 KD.	Oct 11 2023
A2742	Anti-c-RET	Anti-c-RET is a monoclonal antibody against the receptor tyrosine kinase Ret (c-Ret) expressed in cells of neuroblastoma and substantia nigra, a responsive locus of Parkinson's disease. MW: 146.74 KD.	Oct 11 2023
A2778	Garivulimab (Anti-B7-H1 / PD-L1 / CD274)	Garivulimab (Anti-B7-H1 / PD-L1 / CD274) is a humanized immunoglobulin G1 (IgG1)-variant monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. MW: 144.3 KD.	Oct 11 2023
A2798	Certolizumab (Anti-TNFSF2 / TNFa)	Certolizumab (anti-TNFSF2 / TNFa) is a Fab fragment of a recombinant, humanized monoclonal antibody directed against the proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) with anti-inflammatory activity. MW: 144.92 kD.	Oct 11 2023

製品コード	製品名称	製品説明	添加時期
E1754	BRD7389	BRD7389 is an inhibitor of RSK family kinases with IC50 of 1.5 μM, 2.4 μM, and 1.2 μM for RSK1, RSK2, and RSK3, respectively. BRD7389 also increases β-cell–specific gene expression in primary human islet cells.	Mar 06 2024
E1748	HG6-64-1	HG6-64-1 (HMSL 10017-101-1) is a highly potent and selective inhibitor of B-Raf with an IC50 of 0.09 μM on B-raf V600E transformed Ba/F3 cells.	Feb 01 2024
E1649	Exarafenib	Exarafenib(KIN-002787, KIN-2787, RAF/KIN_2787) is an orally-available, selective inhibitor of pan-RAF. Exarafenib is effective in RAF-dependent cancers, including all classes of BRAF alterations. Exarafenib suppresses MAPK signaling in RAF-dependent melanoma cell lines. KIN-2787 exhibits low nanomolar to picomolar potency against RAF1, BRAF, and ARAF with an IC50 of 0.06-3.46 nM with minimal activity towards non-RAF kinases.	Dec 28 2023
E1657	Gamcemetinib (CC-99677)	Gamcemetinib (CC-99677,BMS-986371) is a potent, covalent, and irreversible inhibitor of the mitogen-activated protein (MAP) kinase-activated protein kinase-2 (MK2) (MAPKAPK2 (MK2)) pathway in both biochemical (IC50=156.3 nM) and cell based assays (EC50=89 nM).	Oct 08 2023
E1656	AS601245	AS601245 is an orally active, selective, ATP-competitive JNK (c-Jun NH2-terminal protein kinase) inhibitor with IC50 of 150, 220, and 70 nM for three JNK human isoforms hJNK1, hJNK2, and hJNK3, respectively.	Oct 08 2023
E1395	GW806742X	GW806742X, is a potent inhibitor of MLKL (Mixed Lineage Kinase Domain-Like protein), and binds to the MLKL pseudokinase domain with a Kd of 9.3 μM. GW806742X retards MLKL membrane translocation and inhibits necroptosis.	Jul 23 2023
E1391	SP 600125, negative control	SP 600125, negative control (JNK inhibitor II, negative control) is a methylated analog of SP 600125 and inhibits JNK2 and JNK3 with IC50 of 18 µM and 24 µM, respectively.	May 30 2023
E1297	BGB 15025	BGB-15025 is a potent and selective HPK1 inhibitor. It is used in the treatment of various cancers.	Feb 02 2023
S3493	APS6-45	APS6-45(Compound 10) is an orally active tumor-calibrated inhibitor (TCI) that inhibits RAS/MAPK signaling and exhibits antitumor activity.	Jan 10 2023
E1079	GNE-9815	GNE-9815 is a highly selective, pan-Raf inhibitor with good oral bioavailability. GNE-9815 exhibits Ki values of 0.062 and 0.19 nM for c-Raf and b-Raf, respectively.	Nov 15 2022

製品コード	製品名称	製品説明	添加時期
E1783	Conteltinib(CT-707)	Conteltinib(CT-707) is a potent multikinase inhibitor of ALK, FAK,Pyk2, showing promising anti-tumor activities. Conteltinib exhibits significant inhibitory effects on FAK with an IC50 value of 1.6 nM in vitro kinase assay.	Mar 26 2024
E1114	Ifebemtinib	Ifebemtinib(IN10018, BI853520) is a highly selective, potent inhibitor of focal adhesion kinase (FAK), with an IC50 of 1 nM for inhibiting FAK autophosphorylation. It also inhibits FER Kinase and FES Kinase with IC50s of 900 nM and 1040 nM, respectively, inhibiting spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma. IN10018 exhibits anti-tumor activity in vitro and in vivo.	Mar 25 2024
E1735	PK11007	PK11007 is a thiol-reactive anticancer agent that stabilizes p53 via selective alkylation of two surface cysteines without compromising its DNA binding. It induces mutant p53 cancer cell death by increasing reactive oxygen species (ROS) levels.	Dec 07 2023
S8617	Acriflavine	Acriflavine is a HIF-1 dimerization inhibitor and have potent inhibitory effects on tumor growth and vascularization. It is used as fluorescent dye for labeling high molecular weight RNA.	Nov 14 2023
E1712	FM19G11	FM19G11 is a hypoxia-inducible factor-1-alpha (HIF-1α) inhibitor, and it inhibits hypoxia-induced luciferase activity with an IC50 of 80 nM in HeLa cells.	Nov 08 2023
E1661	Adaptaquin	Adaptaquin is an inhibitor of hypoxia-inducible factor prolyl hydroxylase 2 (HIF-PHD2), with an IC50 of 2 μM. Adaptaquin also inhibits lipid peroxidation and maintains mitochondrial function.	Nov 05 2023
E4474	Infigratinib Phosphate	Infigratinib Phosphate (NVP-BGJ398 phosphate) is the phosphate salt form of infigratinib, an orally bioavailable pan-inhibitor of human fibroblast growth factor receptors (FGFRs) with IC50 of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4 respectively. It also has potential antiangiogenic, antineoplastic and antitumor activities.	Oct 24 2023
A2126	Anti-mouse VEGFR-2-InVivo	Anti-mouse VEGFR-2-InVivo (Clone: DC101) monoclonal antibody reacts with mouse VEGFR-2 (vascular endothelial growth factor receptor 2) also known as CD309, KDR, and Flk-1 and inhibit VEGFR-2 signaling in vivo. VEGFR-2 plays a key role in vascular development and permeability.	Oct 17 2023
A3080	Tomuzotuximab (Anti-ERBB1 / EGFR / HER1)	Tomuzotuximab (Anti-ERBB1 / EGFR / HER1) is a fully human glycoengineered IgG1 monoclonal antibodytargeting EGFR. It has anticancer effects. MW :150 KD.	Oct 11 2023
A2606	Disitamab (Anti-ERBB2 / HER2 / CD340)	Disitamab (Anti-ERBB2 / HER2 / CD340) is a humanized monoclonal antibody targeting HER2. It can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin. It has antitumor and antineoplastic activities. MW :144.16 KD	Oct 11 2023

製品コード	製品名称	製品説明	添加時期
E1731	JW74	JW74 is a specific inhibitor of the canonical Wnt signaling with IC50 790 nM in the ST-Luc assay. It inhibit the growth of tumor cells in both mouse xenograft model of colorectal cancer and in Apc^Min mice.	Nov 26 2023
E1486	Zamaporvint (RXC004)	Zamaporvint (RXC004) is an orally active and selective inhibitor of Wnt. It targets membrane-bound o-acyltransferase Porcupine and inhibits Wnt ligand palmitoylation, secretion, and pathway activation. RXC004 exhibits potent antiproliferative effects in Wnt ligand-dependent colorectal and pancreatic cell lines and possesses multiple antitumor mechanisms.	Oct 11 2023
A2621	Anti-ACVR1 / ALK-2 (DS-6016a)	Anti-ACVR1 / ALK-2 (DS-6016a) monoclonal antibody targeting ALK-2. It can be used in the treatment of fibrodysplasia ossificans progressiva (FOP). MW :145.56.	Oct 11 2023
A2681	Brontictuzumab (Anti-NOTCH1)	Brontictuzumab (Anti-NOTCH1) is a monoclonal antibody that targets Notch1 signal. It inhibits tumor cell proliferation and can be used in the research of leukemia and lymphoma. MW :150 KD.	Oct 11 2023
A2370	Elezanumab (Anti-RGMA)	Elezanumab (Anti-RGMA) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway with IC50 of 97 pM. MW: 146.44 kD.	Aug 10 2023
A2489	Vantictumab (Anti-FZD)	Vantictumab (Anti-FZD) is a monoclonal antibody targeting the Wnt signaling pathway with potential antineoplastic activity. Vantictumab binds to certain receptors in the Wnt signaling pathway thereby preventing the activation of the Wnt signaling pathway. This results in an inhibition of cancer stem cell (CSC) activity and a subsequent inhibition of cancer cell proliferation. MW: 145.5 KD.	Aug 10 2023
E0787	ALLO-2	ALLO-2 is a potent antagonist of both wild-type mouse Smo and drug-resistant D473H mutant human Smo that inhibits Smo agonist inhibited Gli-Luc activity in TM3-Gli-Luc cells with IC50 of 6 nM.	Jul 28 2022
S9965	M435-1279	M435-1279 is a UBE2T inhibitor, inhibiting the Wnt/β-catenin signaling pathway hyperactivation through blocking UBE2T-mediated degradation of RACK1.	Jul 06 2022
E0480	MRT-81	MRT-81 is a potent antagonist of human and rodent smoothened (Smo) receptors, with an IC50 value of 41 nM in the Shh-light2 cells, exerting potent hedgehog (Hh) signaling pathway inhibiting activity.	Jul 01 2022
E0782	MRT 10	MRT-10 inhibits ShhN signaling in Shh-light2 cells in a dose-dependent manner with IC50 of 0.64 μM, showing the capacity to abrogate the constitutive activity of Smo.	Jul 01 2022

製品コード	製品名称	製品説明	添加時期
E1678	SPOP-i-6lc	SPOP-i-6lc is a selective speckle-type POZ protein (SPOP) E3 ubiquitin ligase inhibitor with IC50 of 2.1 μM and 3.5 μM, in A498 and OS-RC-2 cell lines, respectively. In vitro, It suppresses viability and proliferation of A498 and OS-RC-2 kidney cancer cell lines.	Dec 17 2023
E1479	I-138	I-138 is an orally active, potent reversible inhibitor of USP1-UAF1 with IC50 0f 4.1 nM. I-138 is structurally related to ML323 and induces the monoubiquitination of FANCD2 and PCNA in MDA-MB-436 cells and increases PCNA and FANCD2 monoubiquitination in HAP-1 USP1 WT cells.	Oct 11 2023
A2727	Anti-Polyubiquitin	Anti-Polyubiquitin is a monoclonal anti-Polyubiquitin antibody used for isolating polyubiquitin chain-tagged proteins. MW: 144.98 KD.	Oct 11 2023
E1214	KSQ-4279	KSQ-4279 (USP1-IN-1) is an orally bioavailable selective inhibitor of the ubiquitin specific protease 1 (USP1) with anti-proliferative activity. KSQ-4279 also exhibits synergistic activity in combination with PARP inhibitors.	Aug 29 2023
E1389	Eeyarestatin I	Eeyarestatin I is a potent inhibitor of endoplasmic reticulum-associated protein degradation (ERAD). Eeyarestatin I also inhibits Sec61 translocon.	Jul 27 2023
E1427	MRT-2359	MRT-2359 is a potent degrader of GSPT1. It exhibits anti-tumor activity in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cells.	Jul 27 2023
E1300	SJ6986	SJ6986 is a CRBN modulator and specifically degrades GSPT1/2, with a DC50 of 2.1 nM (Dmax 99%) for GSPT1.	May 08 2023
E1330	Usp22i-S02	Usp22i-S02(USP22-IN-1, compound S02) is a potent inhibitor of ubiquitin specific peptidase 22 (USP22). It showed anticancer activity by suppressing Foxp3 expression in T-regulatory cells.	Mar 08 2023
S9865	CB-5339	CB-5339 is a potent p97/Valosin Containing Protein (VCP) inhibitor with an IC50 of 9 nM.	Jan 06 2023
S1015	Thalidomide-OH	Thalidomide-OH (Cereblon ligand 2, E3 ligase Ligand 2) is a presumed hydroxylated thalidomide metabolite, with weak antiangiogenic activity (the average inhibition rate of vessel density was 14% in 100 μg), also can be applicable to the recruitment of CRBN protein.	Jul 28 2022

製品コード	製品名称	製品説明	添加時期
E1876	GTS-21 dihydrochloride	GTS-21 dihydrochloride(DMXB-A; DMBX-anabaseine) is a selective agonist of alpha7 nicotinic acetylcholine receptor (α7-nAChR) and exhibits anti‑inflammatory and cognition‑enhancing activities. GTS-21 dihydrochloride is also an antagonist of α4β2 with a Ki value of 20 nM for humanα4β2 and 5-HT3A receptor with an IC50 value of 3.1 μM.	Apr 10 2024
E1781	Biricodar	Biricodar(VX-710) is a modulator of P-glycoprotein and MRP-1 with minimal in vivo toxicity. It enhances the effectiveness of various antibiotics against numerous gram-positive pathogens and exhibits potent chemosensitizing properties in cells resistant to multiple drugs.	Mar 31 2024
E1796	Dimethindene maleate	Dimethindene maleate is a selective antagonist of histamine H1 and exhibits antihistamine effects. It suppresses the cromakalim-induced/glibenclamide-sensitive K+ currents in a concentration-dependent and reversible manner	Feb 26 2024
E1773	Fasoracetam (NS 105)	Fasoracetam (NS 105) is a metabotropic glutamate receptor activator with a potential to treat vascular dementia.	Dec 26 2023
S9460	Ethotoin	Ethotoin (Peganone) is a hydantoin derivative and an orally active anticonvulsant agent. It also exerts an antiepileptic effect and can be used in epilepsy research.	Nov 21 2023
E4477	Lumateperone	Lumateperone (ITI-007) is an antagonist of 5-HT2A receptor with Ki of 0.54 nM. It has anticancer activity and can also be used in studies of psychiatric disorders such as schizophrenia.	Oct 29 2023
A2813	Anti-Amyloid Beta (CSIRO anti-amyloid Beta scFv)	Anti-Amyloid Beta (CSIRO anti-amyloid Beta scFv) is a recombinant monoclonal antibody in a single chain fragment variable (scFv) against amyloid beta, has the potential to be used in Alzheimer's disease (AD) research. MW : 145.14 KD.	Oct 11 2023
A2814	Cudarolimab (Anti-TNFRSF4 / OX40 / CD134)	Cudarolimab (Anti-TNFRSF4 / OX40 / CD134) is an agonistic fully human anti-OX40 (tumor necrosis factor receptor superfamily member 4, TNFRSF4, CD134, OX40L receptor) with potential immune checkpoint inhibitory and antineoplastic activities. MW : 145.94 KD.	Oct 11 2023
A3086	Anti-Amyloid Beta (U.Illinois scFv59)	Anti-Amyloid Beta (U.Illinois scFv59) is a single-chain antibody targeting amyloid-β (Aβ) protein. It can be used in Alzheimer's disease (AD) research. MW :142.56 KD	Oct 11 2023
A2833	Donanemab (Anti-Amyloid Beta)	Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N‐terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research. MW : 145.36 KD.	Oct 11 2023

製品コード	製品名称	製品説明	添加時期
S9716	H3B-8800	H3B-8800 is a potent and orally active modulator of SF3B splicing. H3B-8800 interacts directly with the SF3b complex, demonstrating anti-cancer properties. H3B-8800 holds promise for studying acute myeloid leukemia (AML) with SF3B1 mutations.	Apr 10 2024
E1903	SLU-PP-332	SLU-PP-332 is an agonist of pan-Estrogen Receptor/ERR with EC50 values of 98nM, 230nM, and 430 nM for ERRα, ERRβ, and ERRγ, respectively with the highest potency for ERRα. SLUPP-332 amplifies mitochondrial function and cellular respiration in skeletal muscle cell lines and also offers opportunities for researching metabolic ailments and enhancing muscle functionality.	Apr 10 2024
E1924	TI17	TI17 is an inhibitor of thyroid hormone receptor-interacting protein Trip13. TI17 efficiently suppresses the proliferation of multiple myeloma (MM) cells and triggers cell cycle arrest and apoptosis. Trip13, an AAA-ATPase involved in double-strand break (DSB) repair, is targeted by TI17, leading to impaired function and heightened DNA damage.	Apr 10 2024
E1849	TL12-186	TL12-186 is a cereblon-dependent multi-kinase PROTAC degrader. TL12-186 also inhibits CDK2/cyclin A and CDK9/cyclin T1 with IC50 values of 73 nM and 55 nM, respectively.	Apr 08 2024
E1905	Nalidixic acid sodium salt	Nalidixic acid sodium salt is an inhibitor of bacterial DNA gyrase and topoisomerase IV, essential enzymes for DNA supercoiling during replication, making it an effective quinolone antibiotic against both gram-positive and gram-negative bacteria.	Apr 06 2024
E1694	Sardomozide dihydrochloride	Sardomozide dihydrochloride (CGP 48664A) is a potent inhibitor of S-adenosylmethionine decarboxylase (SAMDC) with an IC50 of 5 nM. It is also a potent inhibitor of polyamine oxidase and exhibits with broad spectrum antiproliferative and antitumor activity.	Mar 07 2024
S7972	Litronesib	Litronesib (LY2523355) is a selective allosteric inhibitor of the human mitosis-specific kinesin Eg5. LY2523355 also exhibits highly schedule-dependent, broad-spectrum anticancer activity against tumor models and causes mitotic arrest and apoptosis in cancer cells.	Mar 07 2024
E1722	Acetalax(Oxyphenisatin acetate)	Oxyphenisatin acetate is the pro-drug of oxyphenisatin. It has antiproliferative activity and also used to be a laxative.	Mar 03 2024
E1614	OUL232	OUL232 (Compound 27) is an potent inhibitor of mono-ADP-ribosylation (mono-ARTs) PARP10 with IC50 of 7.8 nM. It also inhibits PARP7, PARP11, PARP12, PARP14, and PARP15 at nM potencies.	Feb 26 2024
E1810	dCeMM1	dCeMM1 is a degrader of RBM39. dCeMM1 functions by altering the activity of the CRL4DCAF15 ligase, and also decreases RBM39 expression levels in wild-type KBM7 cells.	Jan 22 2024